EAU 2025: Metastatic Hormone Sensitive Prostate Cancer with a Deep Response to ADT plus ARPI: The Pros and Cons of De-escalation of Systemic Therapy Publicado 20 de Noviembre de 202500:18:03ver más
ESMO 2025: 3-Weekly Docetaxel 75 mg/m2 vs 2- Weekly Docetaxel 50 mg/m2 in Combination with Darolutamide + ADT in Patients with mHSPC – Results from the Randomised Phase 3 ARASAFE Trial Publicado 20 de Noviembre de 202500:13:09ver más
ASCO GU 2025: Which Patients with mHSPC Benefit More from Androgen Receptor Pathway Inhibitors? STOPCAP Meta-Analyses of Individual Participant Data Publicado 29 de Noviembre de 202500:18:02ver más
AUA 2025: Who Still Needs a Lymph Node Dissection with a Negative PSMA-PET? Results from the Michigan Urological Surgery Improvement Collaborative Publicado 29 de Noviembre de 202500:14:03ver más
EAU 2025: Patient with High-risk Localised Prostate Cancer - cT3bN0M0 ISUP Grade Group 5: The Urologist, Radiation Oncologist, and Medical Oncologist Perspectives Publicado 29 de Noviembre de 202500:14:16ver más
EAU 2025: State-of-the-Art Lecture Current Landscape of Peri-Operative Therapies in Localized Prostate Cancer: Biomarker-Directed Neoadjuvant Strategies Publicado 29 de Noviembre de 202500:16:25ver más